{"classes":[{"categories":[{"measurements":[{"comment":"The geometric mean and geometric coefficient of variation were not estimable as the samples were below the limit of quantification. The samples were taken prior to administration of the first dose.","groupId":"OG000","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"406"}],"units":"Participants"}],"title":"Pre-infusion on Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"101.8","value":"63.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"402"}],"units":"Participants"}],"title":"15-30 minutes post-infusion on Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"60.0","value":"67.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"388"}],"units":"Participants"}],"title":"2 hours post-infusion on Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"110.7","value":"1.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"383"}],"units":"Participants"}],"title":"Pre-infusion on Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"95.7","value":"1.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"379"}],"units":"Participants"}],"title":"Pre-infusion on Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.4","value":"68.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"375"}],"units":"Participants"}],"title":"15-30 minutes post-infusion on Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"71.0","value":"66.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"358"}],"units":"Participants"}],"title":"2 hours post-infusion on Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"99.3","value":"1.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"336"}],"units":"Participants"}],"title":"Pre-infusion on Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"265.3","value":"0.323"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"323"}],"units":"Participants"}],"title":"Treatment Completion/Discontinuation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"423"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received trastuzumab emtansine, 3.6 mg/kg, IV, Q3W for 14 cycles (1 cycle = 21 days) or until disease recurrence or unacceptable toxicity which ever occurs first.","id":"OG000","title":"Trastuzumab Emtansine"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK)-evaluable population included all participants who received at least 1 dose of trastuzumab emtansine and had at least one evaluable post dose PK sample. Overall number analyzed is the number of participants with data available for analysis. Number analyzed per timepoint are unique number of participants out of all the assessed participants with data available for analysis at the specified timepoint. Different participants may have contributed data for each timepoint.","reportingStatus":"POSTED","timeFrame":"Pre-infusion on Cycles 1, 2, 4 and 5; 15-30 minutes and 2 hours post-infusion on Cycles 1 and 4; treatment discontinuation/completion visit (up to approximately 64 months) (1 cycle = 21 days)","title":"Serum Concentrations of Trastuzumab Emtansine","type":"SECONDARY","unitOfMeasure":"micrograms per milliliter (ug/mL)"}